Comparative pharmacokinetics and pharmcodynamics of recombinant and urinary human chorionic gonadotrophin (rhCG vs uhCG)
A two part study to compare the pharmacological effects of recombinant human chorionic gonadotrophin (rhCG/Ovidrel) versus urinary human chorionic gonadotrophin (uhCG/Pregnyl) given as subcutaneous injection to healthy men following supression of endogenous testosterone (T) and luteinising hormone (LH) with nandrolone decanoate(ND).
Concord Repatriation General Hospital (CRGH)
26 participants
Sep 2, 2009
Interventional
Conditions
Summary
There are currently 2 forms of injectable hCG available in Australia. One is derived from urine (Pregnyl) and the other is genetically engineered (Ovidrel). hCG is used to treat men and women with certain types of infertility. However only Pregnyl is available for use in males. If Pregnyl is withdrawn from the market then there will no alternative form of treatment for infertile men. We aim to compare the action of both forms of hCG in healthy males to determine if Ovidrel has the same pharmacological effects as Pregnyl, when given to men.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Part 1: a randomised single dose two phase cross over study. 10 healthy men will receive intramuscular (IM) nandrolone decanoate (ND) 200mg on day 0. Then will be randomised to recieve 1500iu subcutaneous (s/c) injection of either rhCG (Ovidrel) or uhCG (Pregnyl) on day 3/week one followed by s/c rhCG or uhCG on day 10/ week 2 (crossover design). IM Nandrolone decanoate injections will be repeated on days 4 (100mg), 7 (200mg) and 11 (100mg). Part 2: a parallel (two) group, multi-dose study 16 healthy men will be recruited into the study. After consent is provided, each participant will undergo suppression of endogenous T levels prior to and during gonadotrophin treatment by administration of a 200mg intramuscular injections of ND. IM Nandrolone decanoate injections will be repeated on days 5 (100mg), 7 (200mg) and 12 (100mg). After the first ND injection, men will be randomised to receive either Pregnyl 1500iu or Ovidrel 1500iu by subcutaneous injection on days 3, 5, 7 and 10. All participants will have a single 5ml blood sample taken for Deoxyribonucleic acid (DNA) analysis in order to investigate genetic predictors of variable responses to hCG.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000462280